The history of the discovery and use of probiotic strains in clinical medicine goes back more than a hundred years. Numerous studies in recent years have convincingly demonstrated that modulation of the intestinal microbiota (IM) is one of the key pathogenetic links in the formation and persistence of symptoms of irritable bowel syndrome (IBS), which makes the strategy of prescribing probiotics pathogenetically justified both for the improving the relief of symptoms and for the maintaining long-term remission of the disease. Targeted action and prolongation of the course of therapy to 8–12 weeks are considered as the main principles for prescribing probiotics for IBS, which allows increasing the effectiveness of therapy for patients. From this standpoint, the probiotic strain Bifidobacterium longum 35624® (Symbiosis Alflorex) with high proven efficacy and safety in the treatment of patients with IBS is of particular interest.

Keywords: modulation of intestinal microbiota, Bifidobacterium longum 35624®, functional gastrointestinal disorders, Toll-like receptors, probiotics, irritable bowel syndrome